Efficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitus
Authors:
- Prabhat Kumar SharmaPSPrabhat Kumar Sharma
- V. ViswaprasadVVV. Viswaprasad
- Animesh ChoudharyACAnimesh Choudhary
- Ansari Rizwanahmed NurulhasanANAnsari Rizwanahmed Nurulhasan
- Sagar Vivek RedkarSRSagar Vivek Redkar
- Patel Manan BharatkumarPBPatel Manan Bharatkumar
- Vijaykumar Shivajirao PatilVPVijaykumar Shivajirao Patil
- Sumit AnandSASumit Anand
- Vijaykumar BargeVBVijaykumar Barge
- Shalin J. ShahSSShalin J. Shah
- Chintan B. PatelCPChintan B. Patel
- Kanugula SudheerKSKanugula Sudheer
Open Access
- 20 May 2026
- journal article
- Published by Elsevier in Metabolism Open
- Vol. 30, 100476
Abstract
No abstract availableKeywords
Funding Information
- Zydus Lifesciences
This publication has 25 references indexed in Scilit:
- Design, synthesis, and biological evaluation of long-acting glucagon-like peptide-1 (GLP-1) conjugates modified with dual fatty acids and a proline-alanine-serine (PAS) polypeptideBioorganic & Medicinal Chemistry, 2025
- Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)The Lancet Diabetes & Endocrinology, 2023
- Semaglutide and the risk of diabetic retinopathy—current perspectiveEye, 2021
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trialsDiabetes & Metabolism, 2019
- Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trialThe Lancet Diabetes & Endocrinology, 2019
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trialThe Lancet Diabetes & Endocrinology, 2017
- Cardiovascular safety and benefits of GLP-1 receptor agonistsExpert Opinion on Drug Safety, 2017
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2016
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue SemaglutideJournal of Medicinal Chemistry, 2015
- Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyThe Lancet, 2004